Two families of G protein-coupled receptors of the neurotransmitter dopamine, i.e., dopamine 1-like family (D1-like receptor) and dopamine 2-like family (D2-like receptor), show dopaminergic activity in nerve cells. The D2-like receptor family, composed of D2, D3, and D4 receptors, downregulates the intracellular cAMP signaling pathway, and dopamine receptor agonists reduce the cAMP level in neurons. We previously demonstrated that the cAMP level in epidermal keratinocytes is related to epidermal barrier homeostasis. Since keratinocytes are known to carry various neurotransmitter receptors, we hypothesized that D2-like receptors on keratinocytes might be related to skin barrier homeostasis. In this study, we examined the effect of topical application of receptor agonists and antagonists on skin barrier recovery after barrier disruption. Application of D2-like receptor agonists accelerated barrier recovery, whereas D2-like receptor antagonists delayed it. D2-like receptor agonists also reduced the epidermal hyperplasia induced by barrier disruption under low environmental humidity. Immunohistochemical study and RT-PCR analysis revealed the expression of the D2 receptor in the basal epidermis and the D4 receptor in the uppermost layer of the epidermis. These results suggest that dopaminergic receptors are involved in epidermal barrier homeostasis.
One of the most important roles of the skin is to form a water-impermeable barrier in the uppermost epidermis, called the stratum corneum (SC) . When the barrier is disrupted, a series of homeostatic processes is accelerated and the original barrier function is restored (Elias and Feingold, 2001) . If the disruption is repeated or occurs under a dry condition, however, marked epidermal hyperplasia and inflammation are induced, even if the degree of barrier disruption is relatively small (Denda et al, 1996 (Denda et al, , 1998a . Thus, skin barrier homeostasis is important in relation to skin pathology.
We have recently demonstrated that several ionotropic receptors, which were originally found in the nervous system, play an important role in homeostasis of the skin permeability barrier (Denda et al, 2002a, b; Fuziwara et al, 2003) . For example, topical application of NMDA receptor agonists after barrier disruption delayed the barrier repair, whereas NMDA receptor antagonists accelerated it (Fuziwara et al, 2003) . GABA (A) receptor and purinergic receptor (P2X) also play roles in skin permeability barrier homeostasis (Denda et al, 2002a, b) . These results suggest that various neurotransmitters are involved in epidermal barrier homeostasis.
Not only ionotropic receptors, but also metabotropic receptors are involved in skin barrier homeostasis. Topical application of an adrenergic b-2 receptor antagonist accelerated the barrier recovery. Activation of G s protein-binding protein, an adrenergic b-2 receptor, upregulates intracellular cAMP (Denda et al, 2003a) . We also demonstrated that the level of cAMP in the epidermis is associated with skin barrier homeostasis (Denda et al, 2004) . Increase of cAMP in the epidermis delayed barrier repair, whereas a decrease of cAMP accelerated barrier recovery. Thus, neurotransmitters that activate G s or Go/Gi proteins might affect skin barrier homeostasis.
Dopamine is a neurotransmitter which plays an important role in the central nervous system. There are five subtypes of dopamine receptor, and they have been categorized into two families, i.e., D1-like receptors (D1 and D5) and D2-like receptors (D2, D3, and D4) (Watson and Arkinstall, 1994) . The D2-like receptor agonists activate Go/Gi proteins and inhibit neuronal activity by downregulation of the intracellular cAMP signaling pathway (Watson and Arkinstall, 1994) . Application of dopamine has been reported to decrease mitosis of keratinocytes (Harper and Flaxman, 1975) . Thus, we hypothesized that the D2-like receptor exists on epidermal keratinocytes and plays an important role in cutaneous barrier homeostasis through the regulation of intracellular cAMP in epidermal keratinocytes. In this study, we first examined the effects of topical application of D2-like receptor agonists and antagonists on skin barrier homeostasis and epidermal proliferation. We also examined the localization of D2-like receptors in the epidermis of hairless mouse. Then, we investigated the effects of D2-like receptor agonists and antagonists on the level of cAMP in the epidermis, and on keratinocyte proliferation.
Results
We first evaluated the effects of topical application of agonists and antagonists of the D2-like receptor on the barrier recovery rate (Fig 1A, B) . Each reagent was applied immediately after tape stripping. Topical application of D2-like receptor agonists, quinpirole, bromocriptine, and PD168077, accelerated barrier recovery (Fig 1A) . On the other hand, application of D2-like receptor antagonists, L-741626, L-741742, and remoxidride, delayed barrier repair (Fig 1B) . These results suggest that activation of the D2-like receptors accelerated barrier recovery, whereas application of antagonists delayed the recovery.
We next examined the effects of topical application of an agonist and antagonist of D2-like receptors on epidermal proliferation induced by barrier disruption under low environmental humidity (Denda et al, 1998a) . The results are shown in Fig 2A and representative microscopic images are shown in Fig 2B-E (B, untreated control; C, acetone-treated skin; D, bromocriptin-treated skin; E, L-741626-treated skin, scale bars ¼ 10 mm). Topical application of the D2-like receptor agonist bromocriptine reduced the epidermal hyperproliferation induced by barrier disruption under low environmental humidity, whereas L-741,626, a D2-like receptor antagonist, enhanced epidermal hyperplasia. These results suggest that D2-like receptors might be involved in the epidermal proliferative responses.
The results of immunohistochemical study and RT-PCR analysis are shown in Fig 3 (A, D2 ; B, D4; C, control). Immunoreactivity with dopamine D2 receptor antibody was observed in the basal layer of the epidermis, whereas immunoreactivity to dopamine D4 receptor antibody was observed in the uppermost part of the epidermis. Immunoreactivity against D3 receptor antibody was not observed in the hairless mouse epidermis (data not shown). RT-PCR analysis for mouse D2 receptor and D4 receptor using total RNA from mouse epidermis also showed positive bands of the expected sizes ( Fig 3D) .
We recently demonstrated that the cAMP level in the epidermis is associated with barrier homeostasis (Denda et al, 2004) . In that study, barrier disruption increased the cAMP level in the epidermis and application of a cAMP antagonist accelerated barrier recovery. In this study, barrier disruption increased the intracellular cAMP level and the increase was reduced by bromocriptine and quinpirole, both D2-like receptor agonists, and also by PD168077, a D4 receptor agonist (Fig 4) . On the other hand, application of L-741626, a D2 receptor antagonist, and L-741742, a D4 receptor antagonist, significantly enhanced the elevation of cAMP by tape stripping. These results support our previous findings (Denda et al, 2004) , i.e., a reduction of cAMP in the epidermis accelerated barrier recovery and an increase of cAMP delayed it.
As shown in Fig 2, application of D2-like receptor antagonists delayed barrier repair. This suggests the existence of endogenous dopamine in the epidermis. Ramchand et al (1995) suggested the existence of a dopamine-synthesizing Figure 1 Topical application of dopamine D2-like receptor agonists and antagonists affected the skin barrier recovery rate. (A) Topical application of agonists of D2-like receptors, quinpirole (1 mM), bromocriptine (100 nM), and PD168077 (100 nM), accelerated skin barrier recovery measured at 1, 3, and 6 h after tape stripping. (B) Topical application of antagonists of D2-like receptors, L-741626 (100 nM), L-741742 (100 nM), and remoxipride (1 mM), delayed skin barrier recovery at 1, 3, and 6 h after tape stripping. Concentration of all reagents was 1 mM. Four mice were used for each measurement. The ordinate shows percent recovery of the barrier with respect to the original level. Ã po0.05; ÃÃ po0.005; ÃÃÃ po0.0005; bar, SD.
Figure 2
Localization of dopamine D2 and D4 receptor in the epidermis. Topical application of 100 nM bromocriptine, a D2-like receptor agonist, reduced epidermal hyperproliferation induced by barrier disruption under low environmental humidity, whereas application of 100 nM L-741626, a D2-like receptor antagonist, enhanced epidermal hyperproliferation. (A) Quantitative results. p ¼ 0.0156 for difference between control and bromocriptine. Thus, application of bromocriptine significantly, though not completely, blocked the epidermal hyperplasia following tape stripping. (B) Untreated control, (C) acetone-treated skin in a dry condition, (D) bromocriptinetreated skin after acetone treatment, (E) L-741626-treated skin after acetone treatment. Scale bars ¼ 10 mm. enzyme in keratinocytes. We detected secretion of dopamine into the medium of keratinocyte culture (Fig 5) . The baseline level of dopamine in the initial medium was 2.22 nM, whereas the medium after the culture of keratinocytes contained 8.62 nM dopamine, i.e., at least 6.40 nM dopamine had been synthesized by keratinocytes during the incubation. The dopamine level in epidermis from four hairless mice was 18.24 nmol per mg protein (SD ¼ 0.74).
We next evaluated the effect of bromocriptine on the delay of barrier repair induced by the application of fors-
Figure 3
Immunoreactivity to anti-D2 receptor antibody is seen in the basal layer of the epidermis (A), whereas immunoreactivity to anti-D4 receptor antibody is seen in the upper layer (B). (C) The results of staining without the first antiserum as a control. RT-PCR analysis for mouse D2 and D4 receptors using total RNA from mouse epidermis also showed positive bands of the expected sizes (D).
Figure 4
The level of cAMP in the epidermis was increased by barrier disruption in agreement with our previous findings (Denda et al, 2004) . The increase was partially blocked by bromocriptine, quinpirole (a D2-like agonist), and PD168077 (a D4 agonist). On the other hand, the increase was enhanced by L-741626 (a D2 antagonist) and L-741742 (a D4 antagonist). The error bars show SD.
Figure 5
Detection of dopamine in the incubation medium of keratinocytes. The small peak, appearing at the same retention time in the control, might have originated from dopamine contaminating the medium. The baseline level of dopamine in the initial medium was 2.22 nM, whereas the medium after the incubation of keratinocytes contained 8.62 nM dopamine, i.e., at least 6.40 nM dopamine was synthesized by keratinocytes during the incubation. X axis shows the potential (mV) which correlated to the amount of oxidated dopamine.
kolin, which increases the intracellular cAMP level. As shown in Fig 6 , the delay of barrier repair induced by forskolin was blocked by the pre-application of bromocriptine.
Finally, we examined the effect of bromocriptine (a D2-like receptor agonist) and L-741626 (a D2 receptor antagonist) on keratinocyte proliferation in culture. As shown in Fig 7A, bromocriptine significantly reduced keratinocyte proliferation. This is consistent with the in vivo data in Fig 2. Application of L-741626, however, did not have any significant effect in this in vitro study. In the in vivo study (Fig 2) , topical application of L-741626 significantly enhanced epidermal hyperplasia induced by barrier disruption. This in vivo effect of L-741626 might be due to elongation of the delay in barrier recovery, as shown in Fig 1. The results of Alamar Blue assay are shown in Fig 7B. The levels of fluorescence indicate the activity of mitochondria, which is considered to be a measure of the viability of the cells (Reid et al, 2001) . In this study, the viability closely paralleled the cell number, indicating that the reduction of keratinocyte proliferation by bromocriptine was not due to cytotoxicity of the reagent.
Discussion
We previously demonstrated that several neurotransmitters are involved in epidermal permeability barrier function. For example, topical application of an NMDA agonist, nicotine, and ATP delayed barrier recovery, whereas application of GABA and glycine accelerated it (Denda et al, 2002a (Denda et al, , b, 2003b Fuziwara et al, 2003) . These results suggest that the ion flux through ionotropic receptors is associated with skin barrier homeostasis (Denda et al, 2003b) .
The D2-like receptor is not an ionotropic receptor, but a Gi/o protein-coupled receptor, which induces a second messenger in the cell. Recently, we demonstrated that adrenergic b2 receptor, which is also not an ionotropic receptor, is involved in skin barrier homeostasis (Denda et al, 2003a) . Topical application of a b2 receptor agonist delayed barrier repair, whereas application of an adrenergic b2 receptor antagonist accelerated it. The adrenergic b2 receptor is a Gs protein-coupled receptor, and its activation increases the cAMP level. We demonstrated that barrier disruption increased the cAMP level in the epidermis, and topical application of an antagonist of cAMP after barrier disruption accelerated barrier recovery, whereas application of folskolin, which accelerates cAMP synthesis, delayed barrier recovery. The dopaminergic D2-like receptor is a Gi/ o protein-coupled receptor, and activation of Gi/o reduces intracellular cAMP. As shown in Fig 4, bromocriptine reduced the increase of cAMP caused by barrier disruption. The level of intracellular cAMP might be a crucial factor in epidermal barrier homeostasis.
Application of a D2-like receptor antagonist alone delayed barrier repair. This result suggested the existence of an endogenous ligand of the receptor in the epidermis after barrier disruption. Ramchand et al (1995) suggested that epidermal keratinocytes can produce dopamine. Figure 5 also indicates that dopamine is secreted from keratinocytes. We previously demonstrated that neurotransmitters, such as ATP and glutamate, were released from the epidermis immediately after skin barrier disruption (Denda et al, 2002a; Fuziwara et al, 2003) . Dopamine might also be secreted in response to barrier disruption. Grando (1997) demonstrated that two types of cholinergic receptors are localized differently in the epidermis. Muscarinic acetylcholine receptors are localized in the basal Figure 6 Forskolin (100 lM)-induced delay of barrier recovery was blocked by pre-application of bromocriptine (1 mM). A-C showed percent barrier recovery 1, 3, and 6 h after tape stripping and following the topical application of the reagents. layer of the epidermis, whereas nicotinic acetylcholine receptors are localized in the upper layer. He suggested that these receptors play different roles in the epidermis and maintain a balance of proliferation and differentiation of the epidermis (Grando, 1997) . In this study, two types of dopamine receptor protein showed different localization in the epidermis. D4, which is localized in the uppermost part of the epidermis, might be involved in barrier homeostasis, whereas D2 might play a role in the proliferative response in the basal layer of the epidermis. The roles of these proteins remain to be fully clarified.
In this study, D2 receptor agonist and antagonist affected the barrier homeostasis, even though D2 receptors were observed in the basal layer of the epidermis. Here, it is important to recognize the cross reactivity between D2-receptor reagents and D4-receptor reagents. The term D2-like receptor refers to D2, D3, and D4 receptors, whereas D1, D5, and D5 receptors are categorized as D1-like receptor. D2-receptor reagents often affect D4 receptor and D4-receptor reagents also often affect D2 receptor (Seeman and Van Tol, 1994 ). The two receptors have similar effects on intracellular cAMP levels, as we demonstrated in this study. Thus, D2 receptor reagents might affect keratinocytes in the uppermost epidermis via D4 receptors to influence barrier repair, whereas D4 receptor reagents might affect keratinocytes in the basal layer of the epidermis via D2 receptors. Another possibility is the existence of unknown signaling between the uppermost epidermis and the basal layer. For example, when the intracellular cAMP level changes, the electrical potential of the keratinocyte membrane is altered, and this in turn affects the adjacent cells via voltage-gated ion channels. Thus, stimulation of basal keratinocyes might affect barrier homeostasis through signal transmission to keratinocytes at the uppermost epidermis. Further study is needed to examine this possibility.
Previous studies have demonstrated that acceleration of barrier recovery also inhibits epidermal hyperplasia following barrier disruption (Denda et al, 1997; Ashida et al, 2001) . In this study, acceleration of the barrier recovery by a D2-like receptor agonist reduced epidermal hyperplasia under low environmental humidity. These results suggest a new strategy for preventing dermatoses, which are characterized by epidermal proliferation and barrier dysfunction.
In conclusion, topical application of D2-like receptor agonists accelerated barrier recovery whereas the application of D2-like receptor antagonists delayed it. Application of a D2-like receptor agonist also blocked epidermal hyperplasia induced by barrier disruption in a dry environment. Immunoreactivity to D2-receptor protein antibody and D4-receptor antibody was observed in the epidermis. These results suggest that dopaminergic receptors play an important role in skin permeability barrier homeostasis.
Materials and Methods
All experiments were performed on 7-13-wk-old male hairless mice (HR-1, Hoshino, Yashio, Saitama, Japan). All procedures for measuring skin barrier function, disrupting the barrier and applying samples were carried out under anesthesia. All experiments were approved by the Animal Research Committee of the Shiseido Research Center in accordance with the National Research Council Guide (National Research Council, 1996) . L-741626 (D2 antagonist), remoxpride (D2-like antagonist, K i value (nM) D2-300, D3-1699, D4-2800), bromocriptine (D2-like agonist, K i value (nM) D2-8, D3-5, D4-290), PD168077 (D4 agonist), quinpirole (D2-like agonist), and L-741742 (D4 antagonist) (Seeman and Van Tol, 1994) were purchased from Tocris Cookson (Avonmouth, UK).
Cutaneous barrier function Permeability barrier function was evaluated by measurement of transepidermal water loss (TEWL) with an electric moisture analyzer (Meeco, Warrington, Pennsylvana), as described previously (Denda et al, 1998a) . Four mice were used for each treatment. For barrier recovery experiments, the skin on both flanks was treated with repeated tape stripping until the TEWL reached 7-10 mg per cm 2 per h, as described previously (Denda et al, 1998b) . Immediately after barrier disruption, 100 mL of an aqueous solution containing the reagent or water alone (control) was applied to the treated area. A different reagent was applied on the other flank. The areas were covered with plastic film for 15 min, then the plastic was removed. Two points on each flank were measured and 4-8 mice were used to evaluate the effects of each treatment. We always disrupted the barrier between 7:00 AM and 8:00 AM and immediately carried out measurements of barrier repair to avoid any influence of circadian rhythm on the barrier repair (Denda and Tsuchiya, 2000) . TEWL was then measured over the same sites at 1, 3, and 6 h after barrier disruption. The barrier recovery results are expressed as percent recovery, because of variations from day to day in the extent of barrier disruption. In each animal, the percent recovery was calculated by means of the following formula: (TEWL immediately after barrier disruptionÀTEWL at indicated time point)/(TEWL immediately after barrier disruptionbaseline TEWL) Â 100%.
Epidermal hyperplasia induced by barrier disruption under low environmental humidity Animals were kept separately in 7.2 L cages in which the relative humidity was maintained at less than 10% with dry air as described previously (Denda et al, 1998a) . Four mice were used for each treatment. The temperature was the same in all cases (221C-251C), and fresh air was circulated 100 times per hour. Animals were kept out of the direct stream of air. During the experiments, the animals' behavior was not restricted. The level of NH 3 was always below 1 ppm. Animals were first kept in a dry condition for 48 h and then the skin on both flanks was treated with acetone-soaked cotton balls, as described previously (Denda et al, 1998a) . The procedure was terminated when TEWL reached 2.5-3.5 mg per cm 2 per h. Immediately after the barrier disruption, 100 mL of L-741624 (100 nM), bromocriptine (100 nM), remoxpride (1 mM), PDI68077 (100 nM), quinpirole (1 mM), or L-741742 (100 nM) was applied to the treated area of one flank. Water was applied on the other flank. Then the animals were again kept in a dry condition for 48 h. After the experiments, animals were euthanized with diethylether inhalation and skin samples were taken from the treated area. One hour prior to this, 20 mL per g body weight of 10 mM bromodeoxyuridine (BrdU) solution was injected intraperitoneally. Untreated control mice were also treated with BrdU at the same time. After fixation with 4% paraformaldehyde, full thickness skin samples were embedded in paraffin, sectioned (4 mm), and processed for hematoxylin and eosin staining. On each section, five areas were selected at random; the thickness of the epidermis was measured with an optical micrometer, and the mean value was calculated. For the assessment of DNA synthesis, the sections were immunostained with anti-BrdU antibodies. On each section, five areas were selected at random from one section; the number of immunostained cells per 1 mm of epidermis was counted and the mean value was calculated. Measurements were carried out in an observer-blinded fashion.
Immunohistochemistry Polyclonal antisera to D2, D3, and D4 receptors were purchased from Alpha Diagnostic International (San Antonio, Texas). The antiserum was diluted 500:1 with blocking solution, i.e., 3% bovine albumin PBS solution containing 10% heat-inactivated goat serum and 0.4% Triton X-100. A fluorescent secondary antibody was purchased from Molecular Probes (Eugene, Oregon) (Alexa Fluor 594, anti-rabbit IgG conjugate). The secondary antibody was also diluted 500:1 with the blocking solution. A 5 mm frozen skin section was fixed with À201C methanol for 10 min, soaked in PBS solution, and blocked with blocking solution for 1 h at room temperature. The section was covered with diluted antiserum solution and kept at 41C overnight. It was then washed with PBS solution containing 0.05% Tween 20 for 15 min three times and covered with the secondary fluorescent antibody solution for 1 h at room temperature. Then the section was washed with PBS solution containing 0.05% Tween 20 for 15 min three times, and mounted with Vectashield (Vectashield with dapi, Vector Laboratories, Burlingame, California). The section was observed and photographs were taken within 6 h.
RT-PCR Epidermis of the skin tissue was removed by incubation with 10 mM EDTA PBS solution at 371C for 30 min. Mouse total RNA was obtained from epidermis using TRIzol reagent (Gibco, BRL, Grand Island, New York). cDNA was produced from the RNA by oligo dT priming and reverse transcription was done using SuperScript II (Life Technologies), according to the manufacturer's instructions. RT-PCR was carried out using a TaKaRa ExTaq Hot Start Kit (Takara Shuzo, Shiga, Japan) with sense and antisense oligonucleotide primers designed for mouse D2 receptor and D4 receptor, respectively (D2 NCBI accession number: NM 010077 and D4: NM 007878). The primer sequences were as follows: D2 sense: AACAGTGCCGTGAACCCCATCATCTATACC, antisense: CCTTCTCTTCTACCACCTGATCCAACATAG, D4 sense: CTCTCC CGCAACCTCCTGAGCCGTCTTCCC, antisense: CACACAGTCTT GGAACTCCTTGACCTCTGC. The denaturing temperature and the polymerase working temperature were 981C and 721C for 1 min, respectively. Annealing was carried out at 601C for 1 min. This program was carried out for 35 cycles.
Human keratinocyte cell culture Human neonatal keratinocytes were purchased from BioWhittaker (Walkersville, Maryland). All in vitro cell culture measurements were carried out using human neonatal keratinocytes at the second to fourth passage.
Quantification of dopamine in cultured human keratinocytes Human neonatal keratinocytes were purchased from BioWhittaker. Medium for the culture system was purchased from Sanko Junyaku (Tokyo, Japan, KGM-2). All in vitro cell culture measurements were carried out using human neonatal keratinocytes at the fourth passage. We first seeded 3 Â 10 4 cells. After a 48 h incubation, medium was taken for analysis. At that time, the cells were 80%-90% confluent. Dopamine quantification was performed by high-pressure liquid chromatography (HPLC) with electron capture detection (ECD). A NANOSPACE SI-1 semi-micro HPLC system (Shiseido, Tokyo, Japan) was used for separation. The column was a Capcell Pack C18 UG120 S5 (Shiseido) for HPLC. A NANOSPACE SI-2/3005 (Shiseido) was employed for ECD. The solvent consisted of water-acetonitrile (95:5, vol/vol) containing 0.7 mM sodium octanesulfonate (WAKO, Osaka, Japan), 0.02 mM EDTA 2Na (WAKO), and 0.1 M potassium dihydrogenphosphate (WAKO), adjusted to pH 3.0 with phosphoric acid (WAKO). The solvent flow rate was 100 mL per min at 301C. A 2 mL aliquot was injected into the column and ECD detection was carried out under OX 650 mV (Ag per AgCl). The amount of dopamine was determined using Catecholamines Standard Solution (WAKO).
Quantification of dopamine in hairless mouse epidermis Skin samples (2 Â 2 cm 2 ) were taken from four male hairless mice (8 wk old) and fat was removed with a scalpel. The skin was incubated in the same medium as used in the human culture experiments to remove dopamine from blood or neurons. Then the epidermis was removed by heating (601C for 1 min). The epidermis was homogenized with 1 mL 0.1% Triton-X/0.1 N HCl/10 mM ascorbic acid, and centrifuged in a spin column to remove debris. An aliquot was taken for protein assay and the dopamine quantification by the same method that we used for dopamine assay of cultured human keratinocytes.
cAMP evaluation Mice were euthanized by diethylether inhalation and skin samples were immediately taken from both flanks. The level of cAMP in skin is readily influenced by systemic factors (Saitoh et al, 1980) . Thus, we performed an in vitro study. Pieces of skin from both flanks were placed, epidermis side upwards, in PBS buffer in separate culture dishes kept at 371C, and one of them was tape stripped four times; the other was not treated. Four tape strippings usually reduced the TEWL to approximately 7-10 mg per cm 2 per h. After a 1-h incubation, the skin was put on a hot plate (601C) for 30 s and the epidermis was separated. The epidermis was homogenized in PBS and centrifuged to remove large particles. An aliquot was removed for assay of both cAMP and protein. cAMP in samples containing 0.1 M HCl was quantified by immunoassay with a cAMP enzyme immunoassay (EIA) kit (Sigma, St Louis, Missouri) according to the manufacturer's instructions.
Evaluation of the effects of bromocriptine and L-741626 on keratinocyte proliferation We used second-to-fourth-passage keratinocytes in this study. There was no significant difference between the results obtained with second-and fourth-passage cells. First, we seeded 3 Â 10 4 keratinocytes per well in 12-well plates with 2 mL of KG2 medium (Kurabo, Osaka, Japan) and incubated them for 48 h. Then, the medium was changed and bromocriptine (final concentration 10 nM) or L-741626 (final concentration 10 nM) was applied. Incubation was continued for another 48 h; then the cells were washed with PBS, and treated with 150 mL of 1% trypsin and 1 mM EDTA. Finally, 150 mL of 1% trypsin inhibitor was added, and the cells in a 10 mL aliquot of the 300 mL suspension were counted. The number of cells per well was calculated.
Alamar blue assay To evaluate the cytotoxicity of bromocriptine and L-741626, we carried out Alamar blue assay (Reid et al, 2001 ). First, we seeded 3x10 4 keratinocytes per well in 12-well plates with 2 mL of KG2 medium (Kurabo) and incubated them for 48 h. Then, the medium was changed and bromocriptine (final concentration 10 nM) or L-741626 (final concentration 10 nM) was applied. Incubation was continued for another 48 h, and then the cells were washed with PBS. The cells were incubated in 1 mL of KG2 medium containing 10% Alamar Blue (TREK Diagnostic Systems, Cleveland, Ohio) for 1 h. Then the fluorescence of each medium was evaluated with a Fluoroskan Ascent FL Plate Reader (Thermo Labsystems, Helsinki, Finland). On the other hand, the cells were washed with PBS, and treated with 150 mL of 1% trypsin and 1 mM EDTA. Finally, 150 mL of 1% trypsin inhibitor was added and the cells in a 10 mL aliquot of the 300 mL suspension were counted. The number of cells per well was calculated.
Statistics The results are expressed as the mean AE SD. The statistical significance of differences between two groups was determined by means of a two-tailed Student's t test. In the case of more than two groups, we first carried out ANOVA and then the significance of differences between groups was determined by means of Fisher's protected least significant difference (PLSD) test. 
